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Background: This study aimed to evaluate the effect of mesenchymal stem cell (MSC)-derived exosomes on an
immune-induced liver injury model. MSCs show a unique function to modulate immune reaction although the
molecular mechanisms are still under investigation. Exosomes are a nanoparticle containing microRNA and many
ligands and are recognized as important factors secreted from MSC to express their function. This research is
undertaken to evaluate the effect of MSC-derived exosome on concanavalin-A (con-A)-induced liver injury.
Methods: Exosomes were collected from the supernatant of MSC from the bone marrow of C57B6 mice with
ultracentrifugation. The collected exosomes or MSCs were injected intravenously into liver injury mice that had
been prepared by the intravenous con-A injection. Liver and serum samples were collected 24 h later to evaluate
the macro- and microscopic images, the alanine aminotransferase (ALT), and cytokine messenger RNA (mRNA)
expression levels. Phenotypical change of non-parenchymal liver cells was also evaluated by flow cytometry. Liver
localization of PKH26 after the injection of PKH26-labeled exosomes or MSCs was observed by microscope. Each
result was statistically analyzed with Student’s t test.
Results: PKH was observed in the liver after PKH-labeled exosomes were injected into mouse, whereas it was only
observed in the lung in a mouse group receiving PKH-leveled MSC. There were decreases in ALT, liver necrotic
areas, and the extent of apoptosis indicated by the single-stranded DNA index of groups that received multiple
injections of MSC-derived exosomes, but an increase in the Ki-67 index. The mRNA expression of anti-
inflammatory cytokines was enhanced. The number of Treg was increased among NPCs in a group
receiving exosomes multiple times.
Conclusions: Suppression of con-A-induced liver injury by injection of exosomes was observed as same
extent as MSC. Considering the advantage of exosomes as its non-living nature and dosing adjustability
over MSC, exosome will be one alternative of MSC transplantation.
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For the success of organ transplantation, it is crucial to
control organ rejection. Although the development of
cyclosporine A and tacrolimus, which suppress interleu-
kin (IL)-2 expression and T cell-mediated immune re-
sponses, was a breakthrough, their adverse effects are
still a major problem in the long-term follow-up of
transplant recipients. In particular, pediatric patients re-
quire long-term immune control, and development of a
novel approach to control organ rejection is desired.
Mesenchymal stem cells (MSCs) have the potential to
self-renew, differentiate into multiple cellular lineages,
and modulate immune properties [1–6]. It has been re-
ported that MSC can be applied as promising immune
modulators to minimize the use of immunosuppressants
and decrease the occurrence of their adverse events
[7–9]. MSC functions are mediated through the secre-
tion of trophic factors in exosomes [10–12]. Exosomes
are nanoparticles consisting of a lipid bilayer, which
transport various molecules for intercellular communi-
cation [13, 14]. MSC-derived exosomes have been re-
ported as a non-cellular alternative to MSC for
transplantation therapy [15–17]. Exosomes are a non-
cellular resource and therefore free from the potential to
differentiate into unintended cellular lineages, which is a
major problem of MSC transplantation [18]. Exosomes
can be injected multiple times, and their characteristics
make the therapeutic use of exosomes more flexible.
The advantages of exosomes provide a therapeutic bene-
fit for younger patients who require more adjustable and
sustainable treatments rather than one-time fixed dosing
such as MSC transplantation.
In this study, we investigated the suppressive effect of
exosomes on an immune-induced liver injury model.
The liver injury was induced by injection of concanava-
lin A (con-A), a lectin derived from jack beans. This type
of liver injury is mediated through activation of the
adaptive immune system including natural killer and
Kupffer cells, which is employed as a method to evaluate
the induction liver tolerance [19–21]. The suppressive
effects of MSC-derived exosomes and the MSCs in this
injury model were evaluated by the level of plasma
alanine aminotransferase (ALT), histopathological exami-
nations, the messenger RNA (mRNA) expression of pro-
and anti-inflammatory cytokines, and the population
alteration of regulatory T cells (Treg) among non-
parenchymal liver cells (NPCs). Additionally, we per-
formed in vivo tracing with fluorescently labeled exosomes
and MSCs in liver tissues.
Methods
Animals and cultivation of MSCs and fibroblasts
Male C57B6 mice were maintained under specific
pathogen-free conditions at the animal facility of KyotoUniversity. All animal experiments were carried out in
accordance with the procedures approved by Animal
Experimentation Committee of Institute for Frontier
Medical Sciences (approval number #F173). MSCs were
harvested from the bone marrow of 8-week-old male
C57B6 mice according to a previous report [22] with
slight modification. In brief, bone marrow cells were col-
lected from the femurs and tibias of mice by flushing
with fresh complete Dulbecco’s modified Eagle’s medium
(DMEM) containing 15% endotoxin-free fetal bovine
serum (FBS) and 1% penicillin-streptomycin. The FBS
had been centrifuged at 100,000g for 3 h at 4 °C to de-
plete vesicles and protein aggregates before use [23].
The bone marrow cells were cultured in complete
DMEM for 3 h before the first medium change. There-
after, the medium was replaced every 8 h for the next
24 h and then every 12 h for the next 48 h. The cells
were washed after 72 h of culture, and the medium was
replaced every 3–4 days. Passaging was carried out at
2 weeks after the initiation of culture and repeated every
7 days. MSCs and the culture supernatants of cells pas-
saged one to three times were used for the following ex-
periments. Harvesting and culture of fibroblasts from
the back skin of 4-week-old male C57B6 mice were car-
ried out according to a previous report [24]. Culture su-
pernatants of fibroblasts passaged one to four times
were used to collect exosomes.
Characterization of MSC and NPC
The differentiation capacity of MSCs for adipocytes, os-
teocytes, and chondrocytes was evaluated using Stem-
Pro® Adipogenesis, Osteogenesis, and Chondrogenesis
Differentiation Kits (Life Technologies, Carisbad, CA,
USA) according to the manufacturer’s protocols. Histo-
chemical staining with oil red O, alizarin red, and alcian
blue was performed as a measure of adipogenesis, osteo-
genesis, and chondrogenesis, respectively, according to
the manufacturers’ protocols.
NPC from harvested liver samples were also collected
according to a previously reported procedure [21]. Pas-
sage 3 MSCs were employed. Their preparation and
staining were carried out based on a previous report
[21]. The monoclonal antibodies (mAbs) are listed in
Table 1. Intracellular staining of FoxP3 in NPCs was car-
ried out using an anti-mouse/rat FoxP3 Staining Set
(eBioscience, San Diego, CA, USA) according to the
manufacturer’s protocol. A FACS CANTO II and FACS
Diva software (BD Bioscience, Franklin Lakes, NJ, USA)
were used for analysis.
Collection of exosomes
Exosomes were purified from the culture supernatants
of MSCs and fibroblasts. Collection was carried out
based on a previous report [14] with slight modification.
Table 1 Antibody used in flow cytometry or
immunofluorescent study





FITC-labeled anti-CD3 Biolegend B134497 17A2
FITC-labeled anti-CD9 eBioscience 11-0091-81 KMC8
FITC-labeled anti-CD31 Biolegend B112061 MEC13.3
FITC-labeled anti-FoxP3 eBioscience 11-5775-80 FJK-16s
PE-labeled anti-CD25 eBioscience 12-0251-81 PC61.5
PE-labeled anti-CD44 BD Bioscience 553134 IM7
PE-labeled anti-CD63 Cosmo Bio Co.
(Tokyo, Japan)
143904 NVG-2













BD Bioscience 552775 RM4-5
Purified anti-F4/80 Biolegend 123109 BM8
Purified anti-CD81 eBioscience 14-0811-81 EAT2
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centrifuged at 2000g and 10,000g for 20 and 30 min, re-
spectively, to deplete cell debris, and the final superna-
tants were filtered through 0.45-μm pore filters [25, 26].
Then, the filtrate was ultracentrifuged to pellet the
exosomes. The total amount of collected exosomes was
determined by measuring the protein concentration with
a BCA assay kit (Thermo Fisher Scientific) according to











IL interleukin, HGF hepatocyte growth factor, TNFα tumor necrosis factor-α, TGFβ tra
glyceraldehyde-3-phosphate dehydrogenaseCharacterization of exosomes collected
The size distribution of the exosomes collected was
determined using a qNano (Izon, Christchurch, New
Zealand) according to the manufacturer’s protocol.
Flow cytometric analysis of exosomes was carried out
according to previous reports [25, 27]. In brief, 10 μg
exosomes was reacted with 20 μl aldehyde/sulfate
beads (4 μm in diameter, Life Technologies) overnight
at 4 °C. After washing with PBS containing 0.2% FBS
and 0.05% sodium azide, the beads were incubated
with anti-CD9 and -CD63 mAbs (Table 1) and then
analyzed. The morphology of exosomes was observed
by transmission electron microscopy (TEM) as re-
ported previously [28].
Fluorescent labeling of exosomes and MSCs with PKH26
Fluorescent labeling of exosomes was carried out ac-
cording to a previously reported procedure [29]. In brief,
100 μg exosomes was reacted with 4 μl PKH26 dye from
a PKH26 staining kit (Sigma-Aldrich, St. Louis, MO,
USA). Fluorescent labeling of MSC was carried out ac-
cording to the manufacturer’s protocol.
Preparation of the mouse liver injury model and
administration of exosomes and MSCs
con-A (Cosmo Bio Co.) in PBS was injected intravenously
(15 mg/kg body weight). Immediately after the injection,
0.1 ml PBS containing 10 μg MSC- or fibroblast-derived
exosomes or 1 × 106 MSC suspended in 0.5 ml PBS was
injected. Specific groups received multiple injections of
MSC- or fibroblast-derived exosomes at 0, 8, and 16 h
after con-A injection. For tracing experiments, the same
amount of PKH26-labeled exosomes or number of MSCs
was employed. Each group included five mice.
Sample collection and immunohistochemical staining of
liver specimens
Liver and blood samples were harvested at 24 h after the










nsforming growth factor-β, INFγ interferon-γ, GAPDH
Fig. 1 Characterization of MSCs and exosomes. a Differentiation of
MSCs into three cellular lineages. i) Microscopy images of MSCs, ii)
MSCs stained with oil red O at 7 days after adipogenic differentiation
culture, iii) MSCs stained with alizarin red staining at 30 days after
osteogenic differentiation culture, and iv) MSCs stained with alcian
blue staining at 18 days after chondrogenic differentiation culture.
b Flow cytometric analysis of MSCs
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periments. The plasma ALT level was measured using a
standard clinical automatic analyzer. Hematoxylin-eosin,
Ki-67, and single-stranded DNA (ssDNA) staining was
carried out using tissue specimens that were fixed in
10% buffered formalin (Wako Pure Chemical Industries
Ltd, Osaka, Japan) overnight and then embedded in
paraffin. Each type of staining was carried out with a
standard protocol. Immunofluorescence staining was
carried out using frozen sections prepared according to
a previous report [28]. Primary and secondary antibodies
used at a dilution of 1:1000 are shown in Table 1.
Observations and imaging analysis were carried out with
a Keyence BZ-X710 fluorescence microscope and BZ-X
analyzer.
mRNA expression analysis of inflammatory cytokines
Total RNA was purified from liver tissue using TRIzol®
Reagent (Thermo Fisher Scientific) according to the man-
ufacturer’s protocol. cDNA was generated from 1 μg puri-
fied RNA using a SuperScript VILO cDNA synthesis kit
(Thermo Fisher Scientific). The cDNA was analyzed using
the Power SYBR® Green quantitative fluorescent PCR
method (Thermo Fisher Scientific) with a 7500 Real-time
PCR system (Applied Biosystems, Foster city, CA, USA).
The primers are summarized in Table 2. The following
PCR conditions were used: 95 °C for 10 min, followed by
40 cycles of 94 °C for 15 s and 60 °C for 30 s.
Glyceraldehyde-3-phosphate dehydrogenase was used as a
housekeeping gene. Fold induction was calculated using





housekeeping)uninfected, and the final data were
derived from 2−∂∂Ct.
Statistical analysis
Data are presented as means ± standard error of the
mean. Comparisons between two groups were carried
out using the two-tailed Student’s t test. Differences
were considered significant at p < 0.05.
Results
Characterization of MSCs and exosomes
Bone marrow-derived cells had a small cell body with
numerous long and thin cell processes (Fig. 1a). Immu-
nohistochemical staining demonstrated their capacity for
adipogenic, osteogenic, and chondrogenic differentiation.
Passage 3 MSCs expressed undifferentiated MSC anti-
gens CD44 and Sca1. CD31, CD34, CD45, CD117, CD3,
and B220 antigens for mesenchymal progenitor cells and
differentiated lymphocytes/leukocytes were scarcely de-
tected (Fig. 1b). The average size of the collected exo-
somes was 135 nm (Fig. 2b). The percentage of exosomes
with CD9 and CD63 surface markers was 20–30% (Fig. 2c).Exosomes showed a typical cup shape of 100–150 nm
(Fig. 2d).
In vivo accumulation of PKH26-labeled exosomes and
MSCs and co-localization of PKH and CD81
PKH26 was observed as bright red spots. PKH26 was
not only observed in the injured liver whereas it was
mainly observed in the lung (Fig. 3a). On the other hand,
PKH26 was detected in injured liver tissue after the
injection of PKH26-labeled exosomes (Fig. 3b). When
intrahepatic sinusoid resident macrophages were visual-
ized by staining the typical marker F4/80, most PKH26
Fig. 2 Characterization of exosomes collected. a Collection procedure for exosomes. b Size distribution of exosomes. c TEM images of exosomes.
d Surface markers of exosomes
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co-localization of PKH and CD81, a common surface
marker of exosomes, was also observed in the liver spe-
cimen (Fig. 4).
In vivo effect of exosomes derived from MSCs and
fibroblasts
The group that received three injections of MSC-
derived exosomes showed significant decreases innecrotic areas (Figs. 5 and 6a) and ssDNA index
(Fig. 6b) and increase of Ki-67 (Fig. 6c) index,
respectively. The percentage ssDNA index was signifi-
cantly decreased in the group that received three in-
jections of MSC-derived exosomes (Fig. 6b), whereas
the percentage of Ki-67-positive cells was significantly
increased in groups that received exosome or MSC
injections (Fig. 6c). Plasma ALT level of same group














Fig. 3 In vivo tracing of PKH26 fluorescent dye-labeled MSCs and exosomes. a Localization of PKH26 dye after the injection of PKH26-
labeled MSC (arrow). White box showed the magnified image of the place where PKH was observed in the lung. b Presence of PKH26
dye in the liver specimen and their co-localization with FITC-stained F4/80-positive cells after the injection of PKH26-labeled exosomes
(arrow). i) PKH26 after the injection of PKH26 labeled-exosomes, ii) FITC-stained F4/80-positive cells, iii) merged image of FITC-stained F4/
80-positive cells and PKH-labeled exosomes, and iv) merged image of PKH26, F4/80-positive cells, PKH26, and DAPI
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that received three injections of fibroblast-derived
exosomes, the values tended to decrease but were not
as low as those in the group received three injections
of MSC-derived exosomes.
mRNA expression of pro- and anti-inflammatory cytokines
and flow cytometric analysis of NPCs
Messenger RNA expression of the pro-inflammatory
cytokine IL-2 was significantly decreased in groups that
received three injections of exosomes or MSCs (Fig. 6e),while that of transforming growth factor β (TGFβ) and
hepatocyte growth factor (HGF) was increased in the
group that received three injections of exosomes. The
percentage of Treg to CD4-positive cells among NPCs
was increased significantly by treatment with exosomes
or MSCs (Fig. 6f, g). The group that received three injec-
tions of exosomes had the most significant increase in
the number of Treg. A statistical difference was ob-
served between the group received three injections of
exosomes and the group that received a single injection
of same exosomes.
Fig. 4 Co-localization of PKH and CD81 on the liver specimen. Co-localization of PKH and CD81, a common surface marker of exosomes, was
shown in the yellow circles in each picture of PKH, CD81, and their merged image with DAPI staining
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The present study demonstrates the promising efficacy
of exosomes on con-A-induced liver injury model in
mouse. Exosomes are interesting and usable biological
nanovesicles that have the ability to carry and transport
many substances into other cells [13, 14]. They are
regarded as a component of the paracrine substances of
MSC and have been applied as therapeutics in animal
models [12, 15]. MSCs were identified as plastic-
adherent, bone marrow-derived cells with a spindle
shape, and their immune-modulating property has been
applied to cell transplantation therapy for various dis-
eases [1, 6, 7, 30]. Multi-lineage differentiation capacity
of MSC used in this study was confirmed by the staining
for adipogenic, osteogenic, and chondrogenic cellular
differentiations (Fig. 1a). Furthermore, flow cytometry
showed the presence of typical MSC markers such as
Sca-1 and CD44 whereas absence of major lineage
differentiation markers such as CD3, B220, and CD45
(Fig. 1b). Exosomes was collected by ultracentrifugation
procedure without density gradient for purification
(Fig. 2a). The average size of exosomes collected was ap-
proximately 135 nm in diameter (Fig. 2b). Exosomes are
often described as extracellular vesicles of smaller than
100 nm in diameter [31]. Based on the results of diam-
eter distribution of exosomes collected by qNano system
and TEM image (Fig. 2b, d), it was possible that the
exosomes collected formed aggregates in the collection
process as reported [32].
In vivo bio-distribution of MSC after the intravenous
injection was still under investigation [33]. In our study,
PKH that was used for labeling of MSC beforeintravenous injection of MSC was only observed in the
lung as reported previously (Fig. 3a) [33]. MSC used in
this study showed its suppressive effect on con-A-
induced liver injury model while it was not observed in
the injured liver, and it is possible to surmise some se-
creting factors from MSC played an important role in
the expression of suppressive effect of MSC. At the same
time, PKH used for labeling of exosomes in this study
was observed in the injured liver (Fig. 3b). In this in vivo
tracing study, most of them were co-localized with F4/
80-positive cells that correspond to Kupffer cells [34].
Kupffer cell is specialized macrophages in the liver and
plays an important role in engulfing of exosomes
[35–37]. It also reported to be involved in the initiation
and suppression of con-A-induced liver injury through
the induction of natural killer and Treg [34, 38–40].
At the same time, co-localization of PHK with CD81,
a common surface marker of exosomes, was observed in
the injured liver specimen (Fig. 4). In this experiment,
PKH was employed to label the surface of MSCs which
were captured in the lung after intravenous injection.
The presence of PKH in the liver and its co-localization
with CD81 implied the releasing factors from MSCs in
the lung reached to the liver specimen, and they pos-
sessed one of the unique surface markers of exosomes.
Multiple injections of MSC-derived exosomes exerted
a significant effect to suppress the liver injury in terms
of necrotic areas and ALT levels, which was similar to
the MSC (Figs. 5 and 6a, d). However, fibroblast-derived
exosomes did not exert a similar effect. It has been re-
ported that the contents of exosomes and their functions
are completely different depending on the character of
Fig. 5 Histological findings of the liver at in vivo experiment with exosomes derived from MSCs and fibroblasts. Hematoxylin-eosin, Ki-67, and
ssDNA staining of the liver of mice received intravenous injections of PBS only (PBS), MSC-derived exosomes once (E0), MSC-derived exosomes
three times (E0/8/16), MSCs (MSC), or fibroblast-derived exosomes three times (Fibro_exo)
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volved in the liver injury model used in this study, which
may be the reason why only exosomes derived from
MSC exerted the suppressive effect [42]. Single-stranded
DNA is a marker of apoptotic cells, and a decrease in
the ssDNA index was only observed in the group that
received three injections of exosomes (Fig. 6b). At the
same time, the number of Ki-67-positive cells was in-
creased in groups that received injections of exosomes
or MSCs (Fig. 6c). Ki-67 expression tended to increase
after severe tissue damage. It is possible that the increase
in Ki-67 expression of the group that received the single
injection of exosomes was due to severe inflammation.
However, the group that received three injections of exo-
somes or MSCs showed an increase in Ki-67 expression,
even though the liver necrosis of both groups appeared
to be less severe (Figs. 5 and 6a, c). This result was
experimentally supported by the enhanced tissue regen-
eration in both groups expressed by a result of Ki-67
index and mRNAs of several cytokines (Fig. 6c, e). [43].
The mRNA expression of TGFβ and HGF, which aremainly involved in liver regeneration, also increased in the
group that received three injections of exosomes (Fig. 6e)
[44]. Considering the suppression of inflammation, these
results imply that the con-A-induced liver injury was
suppressed through decreased induction of hepatocyte
apoptosis and enhancement of tissue regeneration.
In this study, it is interesting that only the group that
received the single injection of exosomes showed en-
hanced expression of inflammatory cytokine mRNAs,
even comparing a group receiving PBS only (Fig. 6e).
Generally, MSC is reported to support the biological
functions of polymorphonuclear cells and macrophages
and consequently contribute to the maintenance of
inflammation in the early phase, whereas it acts as an
anti-suppressant and induces tissue regeneration in late
inflammatory phase [11, 45, 46]. In this study, single
injection of exosomes derived from MSC was carried
out at the acute phase of liver inflammation. Exosomes
are reported to have very short half-life in bloodstream
[28]. Therefore, exosomes injected in this period would
support and enhance the effect of polymorphonuclear
Fig. 6 In vivo effect of exosomes derived from MSC. mRNA expression of pro- and anti-inflammatory cytokines and flow cytometric
analysis of Treg among NPCs. a–c Percentage of necrotic areas in the injured liver evaluated with hematoxylin-eosin staining (a),
ssDNA index (b), and Ki-67 index (c) of mice received intravenous injections of PBS only (PBS), MSC-derived exosomes once (E0),
MSC-derived exosomes three times (E0/8/16), or MSCs (MSC). d Plasma ALT levels. e mRNA expression ratios of pro- and anti-inflammatory
cytokines. f, g Dot plots (f) and percentage (g) of Treg to CD4-positive percentage of Treg to CD4-positive cells among NPCs. †p < 0.05
vs. the group that received a single injection of exosomes
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augment the inflammation in the liver. On the other
hand, mice group received three times injection of exo-
somes showed suppression of liver injury similar extent
to that of MSCs (Fig. 6a–d). In this study, the total
amount of exosomes used in the three injections was ap-
proximately the same as that of exosomes collected from
the culture supernatant of 1 × 106 MSCs. This multiple
injection strategy may mimic the continuous release of
paracrine factors from MSCs and induce tissue
regeneration.
An increase in the number of Treg was observed in
groups that received injections of exosomes or MSCs,
and the highest percentage was observed in the group
that received three injections of exosomes (Fig. 6f, g). It
has been reported that Treg are required to induce im-
mune tolerance in this liver injury model [39, 40]. In
addition, MSC-derived exosomes play an important rolein the induction of Treg, which is observed in tissue re-
generation governed by MSC [47, 48]. Taken together, it
is highly conceivable that the injection of exosomes con-
tributed to the induction of Treg in the injured liver and
the subsequent amelioration of injury and enhancement
of regeneration. The con-A-induced liver injury model is
used to evaluate the tolerogenic effect of therapeutic
molecules [21]. Therefore, we can say with certainty that
the suppressive effect of MSC-derived exosomes shown
in this study implies their immune-modulating property.
MSC-derived exosomes have been reported as a non-
cellular alternative to MSC for transplantation therapy
[15–17]. MSC transplantation is considered to be a
promising adjunctive therapy to minimize the required
amount of current immunosuppressants and to reduce
their adverse effects [9]. However, unintended differenti-
ation of transplanted cells has been reported, which is a
potentially harmful complication of this therapy [18].
Tamura et al. Inflammation and Regeneration  (2016) 36:26 Page 10 of 11Exosomes are a non-cellular resource and therefore free
from such problems. Furthermore, it is possible to
control the dose, frequency, and timing of their adminis-
tration more flexibly. Pediatric recipients of organ trans-
plantation require long-term immune control, and it is
strongly desired to develop a sustainable and adjustable
treatment free from any adverse effects. The use of
MSC-derived exosomes has major advantages to meet
these requirements and may become a promising non-
cellular alternative to MSCs for transplantation therapy.
Conclusions
We demonstrated the suppressive effect of exosomes de-
rived from MSCs on an immune-mediated liver injury
model. MSC-derived exosomes have some advantages
over MSCs and might become a promising alternative to
MSCs for transplantation therapy.
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